The UK and US have concluded a important commercial pact that will maintain no levies on UK pharmaceutical products entering the US market.
The Terms of the Pact
As part of the deal, the UK has committed to raise expenditure on drugs through the public health system. This commitment ensures that import taxes on these key goods will be held at nothing for a period of the next three years.
This agreement is in response to recent warnings to dramatically increase import taxes on branded drug products, with increases floated up to one hundred percent.
"This deal with the Britain reinforces the worldwide climate for cutting-edge drugs and introduces long-overdue fairness to American-British pharmaceutical trade," a statement noted.
Economic Impact
Medicines are one of the Britain's biggest goods shipped to the US, which is easily the primary destination for large companies like GSK and AstraZeneca.
Statistics show that in the one-year period leading up to last September, the UK exported medicines totaling £11.1bn to the US. This amount accounted for nearly one-fifth of British export trade in that timeframe.
"This deal safeguards work, boosts capital expenditure and sets the stage for the UK to establish itself as a global hub for life sciences," a government official stated.
Specific UK Commitments
The agreement includes several key commitments from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it considers new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to raise total NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, refunds topped 20%.
Broader Context
The deal follows a long-running row between the pharmaceutical industry and the UK government over medicine costs and approval rates.
The disagreement were heightened by arguments that American patients were paying a premium for the same drugs than consumers in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been pledged toward American operations.
The Science Minister acknowledged that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had declined as a proportion of its total funding over the previous ten-year period.
